Literature DB >> 35639263

Excision of breast fibroepithelial lesions: when is it still necessary?-A 10-year review of a regional centre.

Dorsa Mousa-Doust1, Carol K Dingee2,1, Leo Chen1, Amy Bazzarelli2,1, Urve Kuusk2,1, Jin-Si Pao2,1, Rebecca Warburton2,1, Elaine C McKevitt3,4.   

Abstract

PURPOSE: Fibroepithelial lesions (FEL) range from benign fibroadenoma (FA) to malignant phyllodes tumor (PT), but can be difficult to diagnose on core needle biopsy (CNB). This study assesses risk factors for phyllodes tumor (PT) and recurrence and whether a policy to excise FELs over 3 cm in size is justified.
METHODS: Patients having surgery for FELs from 2009 to 2018 were identified. The association of clinical, radiology and pathological features with PT and recurrence were evaluated. Trend analysis was used to assess risk of PT based on imaging size.
RESULTS: Of the 616 patients with FELs, 400 were identified as having FA on CNB and 216 were identified as having FEL with a comment of concern for phyllodes tumor (query PT, QPT). PT was identified in 107 cases; 28 had CNB of FA (7.0%), while 79 had QPT (36.6%). Follow-up was available for 86 with a mean of 56 months; six patients had recurrence of PT, all of whom had QPT on CNB. The finding of PT was associated with CNB of QPT, increasing age and size on multivariate logistic regression. All patients diagnosed with PT following CNB of FA had enlarging lesions with a mean size of 38.3 mm.
CONCLUSIONS: Our data does not support routine excision of FELs based on size alone. All patients with QPT on CNB, regardless of size should consider excision due to high risk of PT and recurrence, and the decision to excise FAs to rule out PT should also consider whether the lesion is enlarging.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Core needle biopsy; Fibroadenoma; High-risk breast lesion; Phyllodes tumor; Surgical excision

Mesh:

Year:  2022        PMID: 35639263     DOI: 10.1007/s10549-022-06631-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  19 in total

1.  Core needle biopsy as a diagnostic tool to differentiate phyllodes tumor from fibroadenoma.

Authors:  Ian K Komenaka; Mahmoud El-Tamer; Eliza Pile-Spellman; Hanina Hibshoosh
Journal:  Arch Surg       Date:  2003-09

2.  Clinical and radiologic data and core needle biopsy findings should dictate management of cellular fibroepithelial tumors of the breast.

Authors:  Erika Resetkova; Laila Khazai; Constance T Albarracin; Elsa Arribas
Journal:  Breast J       Date:  2010 Nov-Dec       Impact factor: 2.431

3.  Analysis of patients with phyllodes tumor of the breast.

Authors:  Can Atalay; Volkan Kınaş; Sait Çelebioğlu
Journal:  Ulus Cerrahi Derg       Date:  2014-09-01

4.  Fibroadenoma versus phyllodes tumor: distinguishing factors in patients diagnosed with fibroepithelial lesions after a core needle biopsy.

Authors:  Cholatip Wiratkapun; Pawat Piyapan; Panuwat Lertsithichai; Noppadol Larbcharoensub
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

5.  Fibroepithelial breast lesions diagnosed by core needle biopsy demonstrate a moderate rate of upstaging to phyllodes tumors.

Authors:  Gabriel Marcil; Stephanie Wong; Nora Trabulsi; Alexandra Allard-Coutu; Armen Parsyan; Atilla Omeroglu; Gulbeyaz Atinel; Benoit Mesurolle; Sarkis Meterissian
Journal:  Am J Surg       Date:  2016-12-27       Impact factor: 2.565

6.  Upstaging of Fibroepithelial Lesions: A Single-Institution Experience.

Authors:  Srivarshini Cherukupalli Mohan; Joshua Tseng; Ashley Marumoto; Stephanie Angarita; Farnaz Dadmanesh; Farin Amersi; Armando Giuliano; Alice Chung
Journal:  Ann Surg Oncol       Date:  2021-10-20       Impact factor: 5.344

Review 7.  Myoepithelial and epithelial-myoepithelial, mesenchymal and fibroepithelial breast lesions: updates from the WHO Classification of Tumours of the Breast 2012.

Authors:  Puay Hoon Tan; Ian O Ellis
Journal:  J Clin Pathol       Date:  2013-03-26       Impact factor: 3.411

8.  Incidence and management of complex fibroadenomas.

Authors:  Miri Sklair-Levy; Tamar Sella; Tanir Alweiss; Ilia Craciun; Eugene Libson; Bella Mally
Journal:  AJR Am J Roentgenol       Date:  2008-01       Impact factor: 3.959

9.  Determining whether excision of all fibroepithelial lesions of the breast is needed to exclude phyllodes tumor: upgrade rate of fibroepithelial lesions of the breast to phyllodes tumor.

Authors:  Andrew D Van Osdol; Jeffrey Landercasper; Jeremiah J Andersen; Richard L Ellis; Erin M Gensch; Jeanne M Johnson; Brooke De Maiffe; Kristen A Marcou; Mohammed Al-Hamadani; Choua A Vang
Journal:  JAMA Surg       Date:  2014-10       Impact factor: 14.766

Review 10.  Management of breast fibroadenomas.

Authors:  R Greenberg; Y Skornick; O Kaplan
Journal:  J Gen Intern Med       Date:  1998-09       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.